Metsera (NASDAQ:MTSR) Now Covered by Cantor Fitzgerald

Analysts at Cantor Fitzgerald assumed coverage on shares of Metsera (NASDAQ:MTSR) in a research note issued on Tuesday,Benzinga reports. The brokerage set an “overweight” rating on the stock.

Several other equities research analysts have also recently issued reports on the company. Evercore ISI initiated coverage on Metsera in a research note on Tuesday. They set an “outperform” rating for the company. Guggenheim initiated coverage on Metsera in a report on Tuesday. They issued a “buy” rating and a $56.00 target price on the stock. Finally, Bank of America began coverage on Metsera in a research note on Tuesday. They set a “buy” rating and a $38.00 price target on the stock.

Metsera Stock Up 1.1 %

MTSR opened at $30.15 on Tuesday. Metsera has a 1-year low of $25.06 and a 1-year high of $32.81.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.